Research Analysts Offer Predictions for BRNS Q1 Earnings

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) – Equities researchers at HC Wainwright issued their Q1 2027 EPS estimates for shares of Barinthus Biotherapeutics in a research note issued on Tuesday, August 25th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of ($0.27) per share for the quarter. HC Wainwright also issued estimates for Barinthus Biotherapeutics’ Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.27) EPS, Q4 2027 earnings at ($0.27) EPS and FY2027 earnings at ($1.07) EPS.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02.

Separately, Weiss Ratings lowered Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $4.00.

Barinthus Biotherapeutics Trading Up 9.3%

Barinthus Biotherapeutics stock opened at $0.66 on Wednesday. The company has a fifty day simple moving average of $0.62 and a 200-day simple moving average of $0.63. The stock has a market cap of $26.92 million, a P/E ratio of -0.64 and a beta of -0.39. Barinthus Biotherapeutics has a 12-month low of $0.51 and a 12-month high of $1.83.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its holdings in Barinthus Biotherapeutics by 115.8% during the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after purchasing an additional 76,800 shares in the last quarter. Rangeley Capital LLC boosted its holdings in shares of Barinthus Biotherapeutics by 88.8% in the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after buying an additional 75,024 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its holdings in shares of Barinthus Biotherapeutics by 108.2% in the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after buying an additional 100,000 shares in the last quarter. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.